Moderna (MRNA) Stock May Be Fully Priced As Melanoma Vaccine Data Leaks

• MRNA shares rose ~7x over the past year but trade at 35.9x P/S versus 11.1x industry and 6.7x peers. • Valuation models suggest fair P/S is well below current levels, flagging shares as overvalued. • mRNA flu, bird flu programs and melanoma vaccine data have not closed the valuation gap. Moderna's shares have surged roughly 7x over the past year, even after a recent pullback, raising the question of whether its price is justified by actual sales. News flow around melanoma vaccine trial data and new mRNA flu and bird flu programs has fueled optimism about the pipeline, but the stock's price-to-sales ratio of 35.9x is far above the broader biotech industry average of 11.1x and its closer peer group's 6.7x. Valuation models that adjust for Moderna's growth, margins, size and risk put the fair P/S well below the current level, suggesting the shares are overvalued and that the market may be underweighting execution risk and recent losses. Despite encouraging pipeline headlines, the current price already bakes in a rich premium for Moderna's existing and potential revenue.